Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 10, Number 11—November 2004
THEME ISSUE
ICEID & ICWID 2004

International Conference on Women and Infectious Diseases (ICWID)

Rubella Elimination and Improving Health Care for Women

Carlos Castillo-Solórzano* and Jon Kim Andrus*Comments to Author 
Author affiliations: *Pan American Health Organization Washington, DC, USA

Main Article

Table

Rubella and congenital rubella eliminationa,b

Time Country Target group Vaccine used Coverage achieved (%)
1998–2001 English-speaking Caribbean
18 countries 2.16 million men/women 20–29 y MR and MMR Average 80c
Range 64–97
1999 Chile 2.5 million women 10–29 y R 98
2001 Costa Rica 1.6 million men/women 15–39 y MR 98c
2001
2002 Brazil
13 states
11 states 27 million, women 12–39 yd MR 95
2002 Honduras 3.3 million men 5–39 y
women 5–49 y MR 98
Men 95
Women 98
2004 El Salvador 2.8 million men/women 15–39 y MR 99
Men 93
Women 99
2004 Ecuador 4.8 million men/women 16–39 y MR 100
Men 100
Women 100

aCRS, congenital rubella syndrome; R, rubella containing vaccine; MR, double viral vaccine, measles/rubella containing vaccine; MMR, triple viral
vaccine.
bSource: 12–18.
cMen/women vaccinated in equal proportions.
dSome states modified the age of the group based on the year of the vaccine introduction.

Main Article

TOP